Phase I and pharmacokinetic study of BAY 43-9006 (sorafenib) in patients with Kaposi's sarcoma.

Trial Profile

Phase I and pharmacokinetic study of BAY 43-9006 (sorafenib) in patients with Kaposi's sarcoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Sorafenib (Primary) ; Ritonavir
  • Indications Kaposi's sarcoma
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Most Recent Events

    • 19 Oct 2017 Status changed from completed to discontinued.
    • 19 Oct 2017 Status changed from completed to discontinued.
    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top